1 / 7

Investigating RANKL's Role in Tumor Migration and Bone Metastasis in Breast Cancer

This study explores the effects of RANKL on breast cancer cell migration and bone metastasis. We present experimental data including survival rates, proliferation assays using thymidine uptake, and migration analyses with SDF-1a and RANKL interactions. Supplementary figures illuminate the signaling pathways involved, particularly the roles of ERK1/2 and AKT. The significance of RANKL and its receptor in tumor progression and metastatic behavior is evaluated, offering insights for potential therapeutic strategies in managing breast cancer metastasis.

viveca
Télécharger la présentation

Investigating RANKL's Role in Tumor Migration and Bone Metastasis in Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. a * * ns 3 2 RANK Arbitrary Score 1 0 b RANK 1 2 3 4 5 6 7 8 9 10 11 Metastasis lymph node Primary tumor Normal breast Supplementary Figure 1

  2. Prolactin RANKL RANKL pERK1/2 pERK1/2 pAKT ERK1/2 AKT b-Actin pSTAT5 STAT5 0 5 10 30 60 min RANK min 0 5 10 20 40 5 10 20 40 Control RANKL 120000 60 RANKL / OPG 100000 50 80000 40 % survival 3H thymidine uptake (CPM) 30 60000 20 40000 10 20000 0 0 Control Day 1 Day 3 RANKL UV Control Sorbitol a b c d e Supplementary Figure 2 Anisomycin

  3. 120 100 80 % increased migration 60 40 20 0 SDF-1a [1mg/ml] RANKL [2.5mg/m] SDF-1a [1mg/ml] RANKL [1mg/ml] SDF-1a [0.1mg/ml] RANKL [2.5mg/ml] RANKL [2.5mg/ml] SDF-1a [0.1mg/ml] Supplementary Figure 3

  4. a Control RANKL RANKL b c 160 * 120 Migration toward the tip, mm 80 Control RANKL 40 0 -40 RANKL RANKL OPG Control Supplementary Figure 4

  5. a c 70 60 50 40 % increased migration * 30 RANK * 20 10 b-actin 0 SDF-1a 1 2 RANKL RANKL / OPG SDF-1a / OPG RANKL / a-CXCR4 SDF-1a / a-CXCR4 * 100 100 90 * 80 80 70 60 SDF-1a RANKL 60 % increased migration 50 % migration 40 pERK1/2 40 30 20 20 ERK1/2 10 0 0 0 3 10 30 60 120 min 0 3 10 30 min 6Ckine RANKL CTACK SDF-1a 6Ckine / RANKL CTACK / RANKL SDF-1a / RANKL b d Supplementary Figure 5

  6. a 700 Control B16F10 600 * 500 Tibia Vertebra 400 Bone density (pQCT mg/cm3) 300 b 200 100 0 Total Cortical Trabecular Tumor Control c Supplementary Figure 6

  7. Control Tumor Tumor / OPG a b c * * * * d e f g h i Supplementary Figure 7

More Related